Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023;402:1434–48.
Wang Z, Zhang Y, Xu C, Peng A, Qin H, Yao K. Advancements in age-related macular degeneration treatment: From traditional anti-VEGF to emerging therapies in gene, stem cell, and nanotechnology. Biochem Pharmacol. 2025;236:116902.
Green KR, Beazley-Long N, Lynch AP, Allen CL, Bates DO, Benest AV. Quantification of angiogenesis in laser choroidal neovascularization. Methods Mol Biol. 2022;2441:223–31.
Yang F, Hu R. Efficacy and safety of intravitreal conbercept and triamcinolone acetonide for wet age-related macular degeneration in China: a meta-analysis. Int Ophthalmol. 2024;44:424.
PubMed PubMed Central Google Scholar
Kumar A, Ferro Desideri L, Ting MYL, Anguita R. Perspectives on the currently available pharmacotherapy for wet macular degeneration. Expert Opin Pharmacother. 2024;25:755–67.
Mulligan K, Seabury SA, Dugel PU, Blim JF, Goldman DP, Humayun MS. Economic value of anti-vascular endothelial growth factor treatment for patients with wet age-related macular degeneration in the united states. JAMA Ophthalmol. 2020;138:40–7.
Liu C, Su W, Jiang X, Lv Y, Kong F, Chen Q, et al. A sustainable retinal drug co-delivery for boosting therapeutic efficacy in wAMD: unveiling multifaceted evidence and synergistic mechanisms. Adv Healthc Mater. 2024;13:e2303659.
Huang C, Wang Y, Huang J, Liu H, Chen Z, Jiang Y, et al. A bioengineered anti-VEGF protein with high affinity and high concentration for intravitreal treatment of wet age-related macular degeneration. Bioeng Transl Med. 2024;9:e10632.
Su W, Liu C, Jiang X, Lv Y, Chen Q, Shi J, et al. An intravitreal-injectable hydrogel depot doped borneol-decorated dual-drug-coloaded microemulsions for long-lasting retina delivery and synergistic therapy of wAMD. J Nanobiotechnology. 2023;21:71.
CAS PubMed PubMed Central Google Scholar
Luo Y, Li C. Advances in research related to microrna for diabetic retinopathy. J Diabetes Res. 2024;2024:8520489.
PubMed PubMed Central Google Scholar
Dhillon N, Santiago C. Management of acute proliferative diabetic retinopathy related complications during the first COVID-19 wave. BMC Ophthalmol. 2022;22:119.
CAS PubMed PubMed Central Google Scholar
Li J, Hou H, Li J, Zhang K. Angiopoietins/Tie2 signaling axis and its role in angiogenesis of psoriasis. Acta Histochem. 2025;127: 152228.
Chen-Li G, Martinez-Archer R, Coghi A, Roca JA, Rodriguez FJ, Acaba-Berrocal L, et al. Beyond VEGF: angiopoietin-tie signaling pathway in diabetic retinopathy. J Clin Med. 2024;13:2778.
Wallace RG, Rochfort KD, Barabas P, Curtis TM, Uehara H, Ambati BK, et al. COMP-Ang1: Therapeutic potential of an engineered Angiopoietin-1 variant. Vascul Pharmacol. 2021;141: 106919.
Khan M, Aziz AA, Shafi NA, Abbas T, Khanani AM. Targeting angiopoietin in retinal vascular diseases: a literature review and summary of clinical trials involving faricimab. Cells. 2020.
Zhang Y, Lin S, Liu J, Chen Q, Kang J, Zhong J, et al. Ang1/Tie2/VE-cadherin signaling regulates DPSCs in vascular maturation. J Dent Res. 2024;103:101–10.
Zhang ZS, Yang A, Luo X, Zhou HN, Liu YY, Bao DQ, et al. Pericyte-derived extracellular vesicles improve vascular barrier function in sepsis via the Angpt1/PI3K/AKT pathway and pericyte recruitment: an in vivo and in vitro study. Stem Cell Res Ther. 2025;16:70.
PubMed PubMed Central Google Scholar
Li W, Wei D, Xie X, Liang J, Song K, Huang L. Dl-3-n-Butylphthalide regulates the Ang-1/Ang-2/Tie-2 signaling axis to promote neovascularization in chronic cerebral hypoperfusion. Biomed Pharmacother. 2019;113:108757.
Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of the angiopoietin-TIE pathway. Nat Rev Drug Discov. 2017;16:635–61.
Patel S, Yang E, Milne TJ, Hussaini H, Cooper PR, Friedlander LT. Angiogenic effects of Type 2 diabetes on the dental pulp. Int Endod J. 2025;58:434–48.
Shah AV, Birdsey GM, Peghaire C, Pitulescu ME, Dufton NP, Yang Y, et al. The endothelial transcription factor ERG mediates Angiopoietin-1-dependent control of Notch signalling and vascular stability. Nat Commun. 2017;8:16002.
CAS PubMed PubMed Central Google Scholar
Saini S, Tuli HS, Saini RV, Saini AK, Sak K, Kaur D, et al. Flavonoid-mediated suppression of tumor angiogenesis: roles of Ang-Tie/PI3K/AKT. Pathophysiology. 2024;31:596–607.
PubMed PubMed Central Google Scholar
Tang F, Huang K, Peng B, Deng W, Su N, Xu F, et al. RhoA/ROCK signaling is involved in pathological retinal neovascularization. J Vasc Res. 2023;60:183–92.
Tetik-Elsherbiny N, Elsherbiny A, Setya A, Gahn J, Tang Y, Gupta P, et al. RNF20-mediated transcriptional pausing and VEGFA splicing orchestrate vessel growth. Nat Cardiovasc Res. 2024;3:1199–216.
CAS PubMed PubMed Central Google Scholar
Miyamura Y, Kamei S, Matsuo M, Yamazaki M, Usuki S, Yasunaga K, et al. FOXO1 stimulates tip cell-enriched gene expression in endothelial cells. iScience. 2024;27:109161.
CAS PubMed PubMed Central Google Scholar
Mammoto T, Parikh SM, Mammoto A, Gallagher D, Chan B, Mostoslavsky G, et al. Angiopoietin-1 requires p190 RhoGAP to protect against vascular leakage in vivo. J Biol Chem. 2007;282:23910–8.
Kim I, Kim HG, So JN, Kim JH, Kwak HJ, Koh GY. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3’-Kinase/Akt signal transduction pathway. Circ Res. 2000;86:24–9.
Richter RP, Ashtekar AR, Zheng L, Pretorius D, Kaushlendra T, Sanderson RD, et al. Glycocalyx heparan sulfate cleavage promotes endothelial cell angiopoietin-2 expression by impairing shear stress-related AMPK/FoxO1 signaling. JCI Insight. 2022;7:e155010.
Dharaneeswaran H, Abid MR, Yuan L, Dupuis D, Beeler D, Spokes KC, et al. FOXO1-mediated activation of Akt plays a critical role in vascular homeostasis. Circ Res. 2014;115(2):238–51.
CAS PubMed PubMed Central Google Scholar
Zhang L, Shan Y, Ji X, Zhu M, Li C, Sun Y, et al. Discovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents. Oncotarget. 2017;8:104745–60.
PubMed PubMed Central Google Scholar
Mammoto T, Mammoto A, Ingber DE. Mechanobiology and developmental control. Annu Rev Cell Dev Biol. 2013;29:27–61.
Daly C, Wong V, Burova E, Wei Y, Zabski S, Griffiths J, et al. Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev. 2004;18(9):1060–71.
CAS PubMed PubMed Central Google Scholar
Campochiaro PA, Peters KG. Targeting Tie2 for treatment of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2016;16:126.
Dasgupta S, Saha A, Ganguly N, Bhuniya A, Dhar S, Guha I, et al. NLGP regulates RGS5-TGFbeta axis to promote pericyte-dependent vascular normalization during restricted tumor growth. FASEB J. 2022;36:e22268.
Hwang B, Jeon MY, Jang JH, Cho YL, Lee DG, Min JK, et al. Coactivation of Tie2 and Wnt signaling using an antibody-R-spondin fusion potentiates therapeutic angiogenesis and vessel stabilization in hindlimb ischemia. MAbs. 2024;16:2435478.
PubMed PubMed Central Google Scholar
Sha L, Zhao Y, Li S, Wei D, Tao Y, Wang Y. Insights to Ang/Tie signaling pathway: another rosy dawn for treating retinal and choroidal vascular diseases. J Transl Med. 2024;22:898.
CAS PubMed PubMed Central Google Scholar
Al-Khersan H, Hussain RM, Ciulla TA, Dugel PU. Innovative therapies for neovascular age-related macular degeneration. Expert Opin Pharmacother. 2019;20:1879–91.
Jonas JB. Diabetic retinopathy. Asia Pac J Ophthalmol (Phila). 2024;13:100077.
Arnold C. Gene therapy targets the retina to treat eye disease. Nat Med. 2025;31:2–3.
Chekuri A. Combinatorial gene therapy for gyrate atrophy of the choroid and retina. Mol Ther. 2025;33:2955-56.
Ford JL, Karatza E, Mody H, Nagaraja Shastri P, Khajeh Pour S, Yang TY, et al. Clinical pharmacology perspective on development of adeno-associated virus vector-based retina gene
Comments (0)